Gastrointestinal Cancers Symposium 2015: findings from a phase III study indicate a possible new treatment strategy for patients with advanced colorectal cancer

Results from an international phase III study of patients with advanced colorectal cancer, a disease which is especially difficult to treat once initial therapy ceases to be effective, point towards a more promising second-line treatment strategy for these patients by combining the targeted drug ramucirumab with standard chemotherapy.

The data, also selected for the official press program by the meeting’s co-sponsors, will be presented by Josep Tabernero, Director of the Vall d´Hebron Institute of Oncology (VHIO), at the forthcoming Gastrointestinal Cancers Symposium 2015, January 15 – 17, San Francisco, California.

To view ASCO´s press release now and find out more please visit:

For any additional information please contact: Amanda Wren, Communication Manager, Vall d´Hebron Institute of Oncology (VHIO), Tel. +34 695 207 886, Email:

Related Posts

Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.